JP4908514B2 - アルツハイマー病に特異的なｅｒｋ１／ｅｒｋ２リン酸化比の変化−アルツハイマー病に特異的な分子生物マーカー（ａｄｓｍｂ） - Google Patents

アルツハイマー病に特異的なｅｒｋ１／ｅｒｋ２リン酸化比の変化−アルツハイマー病に特異的な分子生物マーカー（ａｄｓｍｂ） Download PDF

Info

Publication number
JP4908514B2
JP4908514B2 JP2008535546A JP2008535546A JP4908514B2 JP 4908514 B2 JP4908514 B2 JP 4908514B2 JP 2008535546 A JP2008535546 A JP 2008535546A JP 2008535546 A JP2008535546 A JP 2008535546A JP 4908514 B2 JP4908514 B2 JP 4908514B2
Authority
JP
Japan
Prior art keywords
disease
alzheimer
cells
cell
erk1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008535546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009511905A5 (https=
JP2009511905A (ja
Inventor
クハン、タパン・クマー
アルコン、ダニエル・エル．
Original Assignee
ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/036014 external-priority patent/WO2007043998A1/en
Priority claimed from US11/246,524 external-priority patent/US7595167B2/en
Application filed by ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート filed Critical ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート
Priority claimed from PCT/US2006/037186 external-priority patent/WO2007047029A2/en
Publication of JP2009511905A publication Critical patent/JP2009511905A/ja
Publication of JP2009511905A5 publication Critical patent/JP2009511905A5/ja
Application granted granted Critical
Publication of JP4908514B2 publication Critical patent/JP4908514B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008535546A 2005-10-11 2006-09-25 アルツハイマー病に特異的なｅｒｋ１／ｅｒｋ２リン酸化比の変化−アルツハイマー病に特異的な分子生物マーカー（ａｄｓｍｂ） Expired - Fee Related JP4908514B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/US2005/036014 WO2007043998A1 (en) 2005-10-11 2005-10-11 Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio
US11/246,524 US7595167B2 (en) 2005-10-11 2005-10-11 Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
US11/246,524 2005-10-11
USPCT/US2005/036014 2005-10-11
USPCT/US2006/022156 2006-06-07
PCT/US2006/022156 WO2007044094A1 (en) 2005-10-11 2006-06-07 Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
PCT/US2006/037186 WO2007047029A2 (en) 2005-10-11 2006-09-25 Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)

Publications (3)

Publication Number Publication Date
JP2009511905A JP2009511905A (ja) 2009-03-19
JP2009511905A5 JP2009511905A5 (https=) 2009-11-12
JP4908514B2 true JP4908514B2 (ja) 2012-04-04

Family

ID=37067652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008535546A Expired - Fee Related JP4908514B2 (ja) 2005-10-11 2006-09-25 アルツハイマー病に特異的なｅｒｋ１／ｅｒｋ２リン酸化比の変化−アルツハイマー病に特異的な分子生物マーカー（ａｄｓｍｂ）

Country Status (10)

Country Link
US (1) US20180024146A1 (https=)
EP (5) EP2322936A1 (https=)
JP (1) JP4908514B2 (https=)
KR (2) KR20140002073A (https=)
AT (1) ATE431558T1 (https=)
CA (1) CA2625300C (https=)
DE (1) DE602006006855D1 (https=)
ES (5) ES2412268T3 (https=)
TW (2) TW201413246A (https=)
WO (1) WO2007044094A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1549721B (zh) 2001-02-27 2012-03-07 布朗歇特洛克菲勒神经科学研究所 基于促分裂原活化的蛋白激酶的磷酸化诊断阿尔茨海默氏病
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US7595167B2 (en) 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
CN103961347A (zh) * 2006-07-28 2014-08-06 布朗歇特洛克菲勒神经科学研究所 刺激细胞生长、突触重塑和巩固长期记忆的方法
EP3332797A3 (en) 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury
EP2669386A1 (en) 2008-07-28 2013-12-04 Blanchette Rockefeller Neurosciences Institute Stimulus-elicited genomic profile markers of alzheimer's disease
WO2010014585A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
BRPI0914859A2 (pt) * 2008-08-27 2015-11-03 Lundbeck & Co As H método para diagnosticar um distúrbio afetivo, produto de programa de computador, computador, e, método para determinar uma probabilidade de que um indivíduo de teste exiba um sintoma de um distúrbio afetivo
US8658134B2 (en) 2009-10-02 2014-02-25 Blanchette Rockefeller Neurosciences Institute Fibroblast growth patterns for diagnosis of Alzheimer's disease
JP6013184B2 (ja) * 2009-10-02 2016-10-25 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病末梢細胞におけるｐｋｃアイソザイムプロセッシングの異常変化
CA2835686C (en) * 2011-05-12 2019-10-01 Florin V. Chirila Peripheral diagnostic methods for screening alzheimer's disease using beta amyloid and intercellular communication
EP2780316B1 (en) 2011-11-13 2020-04-15 Blanchette Rockefeller Neurosciences Institute Esters of dcpla and methods of treatment using the same
KR101351978B1 (ko) * 2012-10-30 2014-01-16 주식회사 코씨드바이오팜 참치 안구 파쇄물을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물
CA2935266C (en) * 2014-01-03 2022-02-01 Blanchette Rockefeller Neurosciences Institute Convergence of aggregation rate with validated peripheral diagnostics for alzheimer's disease
US11415574B2 (en) 2017-03-31 2022-08-16 NeuroDiagnostics LLC Lymphocyte-based morphometric test for alzheimer's disease
WO2020237203A1 (en) * 2019-05-23 2020-11-26 Indiana University Research And Technology Corporation Methods for objective assessment of memory, early detection of risk for alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4374316B2 (ja) * 1993-01-25 2009-12-02 武田薬品工業株式会社 β−アミロイドまたはその誘導体に対する抗体およびその用途
US6107050A (en) 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US20030108956A1 (en) * 1993-05-03 2003-06-12 Alkon Daniel L. Cell tests for Alzheimer's disease
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
CN1549721B (zh) * 2001-02-27 2012-03-07 布朗歇特洛克菲勒神经科学研究所 基于促分裂原活化的蛋白激酶的磷酸化诊断阿尔茨海默氏病
US6825229B2 (en) * 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
KR100574017B1 (ko) 2003-08-11 2006-04-26 삼성전자주식회사 잉크젯 프린터의 잉크 카트리지
US7199386B2 (en) 2004-07-29 2007-04-03 General Electric Company System and method for detecting defects in a light-management film

Also Published As

Publication number Publication date
TWI448688B (zh) 2014-08-11
EP2322934A1 (en) 2011-05-18
EP2031398B1 (en) 2013-02-13
CA2625300A1 (en) 2007-04-26
EP2317321B1 (en) 2014-04-02
ES2596881T3 (es) 2017-01-12
EP2322934B1 (en) 2016-08-31
KR20140002073A (ko) 2014-01-07
ES2323813T3 (es) 2009-07-24
TW200801515A (en) 2008-01-01
ATE431558T1 (de) 2009-05-15
EP2322936A1 (en) 2011-05-18
EP2339349A1 (en) 2011-06-29
WO2007044094A1 (en) 2007-04-19
KR101375552B1 (ko) 2014-03-24
US20180024146A1 (en) 2018-01-25
TW201413246A (zh) 2014-04-01
EP2339349B1 (en) 2016-08-17
JP2009511905A (ja) 2009-03-19
ES2412268T3 (es) 2013-07-10
EP2317321A1 (en) 2011-05-04
DE602006006855D1 (de) 2009-06-25
ES2477284T3 (es) 2014-07-16
CA2625300C (en) 2018-01-02
ES2588376T3 (es) 2016-11-02
EP2031398A1 (en) 2009-03-04
KR20080066785A (ko) 2008-07-16

Similar Documents

Publication Publication Date Title
KR101375552B1 (ko) 알츠하이머병-특이적 분자 생체 지표(ａｄｓｍｂ)로서 ｅｒｋ1/ｅｒｋ2 포스포릴화비의 알츠하이머병-특이적 변화
US9797913B2 (en) Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB)
US7595167B2 (en) Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
KR100960256B1 (ko) 유사분열 촉진인자-활성화 단백질 키나제 인산화에 근거한 알쯔하이머병 진단
JP2008520203A (ja) アルツハイマー病の診断および治療のためのホスファターゼ２ａ（ｐｐ２ａ）の異常
EP1934618B1 (en) Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)
WO2007043998A1 (en) Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio
US20080076140A1 (en) Biomarkers of Alzheimer's Disease
JP2011516883A (ja) Ｅｒｋ１／ｅｒｋ２のリン酸化比のアルツハイマー病特異的な変化―アルツハイマー病に特異的な分子バイオマーカー（ａｄｓｍｂ）
US20080221042A1 (en) Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB)
KR102314642B1 (ko) 파브리 병 진단용 바이오 마커 및 이의 용도
KR20070084247A (ko) 알츠하이머 질환의 진단 및 치료를 위한 포스파타제 2ａ(ｐｐ2ａ)의 비정상

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110412

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110712

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111012

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111213

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120112

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150120

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees